2/25/11


Akad Nikah

Reception (Minang)


Reception (Jambi)

Greatfull thanks for :

Prewedding & Reception photos : Beeasphotography, Bandung.  (http://www.beeasphoto.com/ & http://www.facebook.com/pages/Beeasphotography/73975522859)

Pelaminan, Baju Resepsi Minang, Make Up Akad/Resepsi, Entertainment : Ibu Ani Zainudin, Bandung. http://ani-zainuddin.blogspot.com/ & http://www.facebook.com/pages/ANI-ZAINUDDIN-Wedding-Organizer-Decoration/107039292650332

Katering : Teratai Catering, Cirebon. http://terataicateringcirebon.blogspot.com/ , http://www.facebook.com/pages/Teratai-Catering-Cirebon/96625668750?v=info & http://terataicateringcirebon.wordpress.com/

Undangan : Sam Arista, Bandung. http://id-id.facebook.com/pages/Sam-arista-wedding-invitation/187259987969735?v=info & http://www.samarista.com/

Souvenir : Purezzento, Bandung. http://purezentos.com/ & http://en-gb.facebook.com/people/Purezento-Cuziloveu/690204238

Akad Nikah Decoration : My mother, aunt Cici, aunt Nova, me, Uni Lia.

Room Decoration : My mother, aunt Cici, aunt Nova.

Wedding room bedcover, gorden, dll : Kembar 7 Gorden, Cirebon.

Kebaya Akad : Mbak Diana, Cirebon.

regards, taniafdi ^_^

Nieuw...

Exposure to Environmental Microorganisms and Childhood Asthma.
Association between Body-Mass Index and Risk of Death in More Than 1 Million Asians.A Recipe for Medical Schools to Produce Primary Care Physicians.


regards, taniafdi ^_^

Mouse Studies Point to Prognostic Test for Prostate Cancer

Some mice, like some men, develop prostate cancer that never spreads beyond the prostate, and researchers have used these mice to learn why only some tumors metastasize and become fatal. By studying genetically engineered mice, the researchers identified four genes that drive the progression of prostate tumors. The corresponding genes in humans also appear to influence the spread of prostate cancer and could become prognostic markers for identifying potentially lethal tumors in patients, the researchers reported online in Nature on February 2.

New tests are needed to distinguish lethal prostate tumors from those that would never cause harm in a man’s lifetime. But, given the enormous intratumoral heterogeneity of human prostate cancers, Dr. Ronald DePinho of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and his colleagues decided to look for prognostic markers in genetically engineered mice, which are more amenable to genetic analysis. Using unbiased approaches, the investigators discovered that a mouse gene called Smad4 constrains the spread of tumor cells.

Additional experiments and lines of evidence, including functional studies and cross-species comparisons of genes, implicated four genes, including Smad4, in the progression of prostate cancer in mice. The researchers concluded that the process is governed largely by the inactivation of the genes Smad4 and Pten and activation of two other genes, cyclinD1 and Spp1.

They next assessed the prognostic value of the corresponding genes in human prostate cancer, using the protein products of the genes as markers. When added to standard clinical parameters such as the Gleason score, the researchers found these markers improved predictions of death from metastatic prostate cancer among men who participated in the Physicians’ Health Study and in a second study.

“We used the mouse models to filter out the intractable genomic complexity that presents itself in early-stage human cancers,” said Dr. DePinho. “And this allowed us to identify a collection of markers that are functionally relevant to the biology of invasion.” A company has licensed the four markers for further development, he added.

http://www.cancer.gov/ncicancerbulletin/020811/page3#d

regards, taniafdi ^_^

Adult Immunization Schedule for 2011 Released

News Author: Laurie Barclay, MD
CME Author: Charles P. Vega, MD
Posted: 01/31/2011
CME/CE Released: 02/03/2011; Valid for credit through 02/03/2012

February 3, 2011 — In October 2010, the Advisory Committee on Immunization Practices (ACIP) approved the Adult Immunization Schedule for 2011, which includes several changes.

The 2011 schedule, which reflects current recommendations for the licensed vaccines, is published in the February 1 issue of the Annals of Internal Medicine. The 2011 schedule was also approved by the American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and the American College of Physicians.

"The notation for seasonal influenza vaccine in the figure and footnotes was changed to reflect the expanded recommendation for annual influenza vaccination for everyone 6 months of age or older, which was approved by ACIP in February 2010," write Abigail Shefer, MD, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, and colleagues. "In October 2010, ACIP issued a permissive recommendation for use of the tetanus, diphtheria, pertussis (Tdap) vaccine in adults aged 65 years or older; approved the recommendation that Tdap can be administered regardless of how much time has elapsed since the last tetanus and diphtheria (Td)–containing vaccine; and approved a recommendation for a 2-dose series of meningococcal vaccine in adults with certain high-risk medical conditions. The vaccines listed in the Figure have been reordered to keep all universally recommended vaccines together (for example, influenza, Td/Tdap, varicella, human papillomavirus [HPV], and zoster)."

Other changes include clarifications to the footnotes for the measles, mumps, rubella; HPV; and Haemophilus influenza type B (Hib) vaccines and for revaccination with pneumococcal polysaccharide (PPSV). A vaccine series does not need to be restarted, regardless of the time elapsed between doses.

Specific Updated Changes
Specific changes in the schedule for 2011 include the following:
  • All persons at least 6 months old, including all adults, should be vaccinated against seasonal influenza. Adults at least 65 years old may receive the high-dose influenza vaccine (Fluzone; sanofi-pasteur, Swiftwater, Pennsylvania), licensed in 2010 for use in this age group, as an option.
  • Persons at least 65 years old in close contact with an infant younger than 12 months should receive Tdap vaccine, and all persons at least 65 years old may receive Tdap vaccine. Tdap should be administered regardless of time elapsed since receiving the last Td-containing vaccine.
  • Either quadrivalent human papillomavirus (HPV4) vaccine or bivalent (HPV2) vaccine is recommended for girls and women.
  • For revaccination with PPSV, 1-time revaccination after 5 years applies only to persons 19 through 64 years old with indicated chronic conditions, namely chronic renal failure or the nephrotic syndrome, functional or anatomic asplenia, or immunocompromising conditions.
  • For adults with anatomic or functional asplenia or persistent complement component deficiencies and adults with HIV infection who are vaccinated with meningococcal conjugate vaccine (MCV4), a 2-dose series of meningococcal vaccine is recommended, with the 2 doses given 2 months apart. For those with other indications, a single dose of meningococcal vaccine is still recommended. Information in the new schedule clarifies that MCV4 is a quadrivalent vaccine.
  • Information regarding the Hib vaccine clarifies which high-risk persons may receive 1 dose of Hib vaccine, namely persons who have sickle cell disease, leukemia, or HIV infection, or those who have had a splenectomy, if they have not previously received Hib vaccine.
Additional Schedule Highlights
Additional highlights of the Adult Immunization Schedule include the following:
  • Adults younger than 65 years whose previous Td status is unknown should receive 1 dose of Tdap. Tdap should be administered immediately to postpartum women, close contacts of infants younger than 12 months, and healthcare workers.
  • Girls 11 to 12 years old should receive HPV4 or HPV2. Catch-up vaccination in girls may be given until age 26 years. Boys and men 9 to 26 years old may be given HPV4 to lower their risk of acquiring genital warts.
  • All persons at least 60 years old should receive a single dose of vaccine against herpes zoster, regardless of whether personal history is positive for herpes zoster.
  • Recommendations for varicella vaccination are unchanged. Two vaccine doses at least 4 weeks apart should be given to all adults born during or after 1980 who have no evidence of immunity to varicella. Healthcare workers should not be considered to have immunity against varicella simply because of their age. Pregnant women should be evaluated for evidence of varicella immunity, and those lacking such evidence should receive the first dose of varicella vaccine on completion or termination of pregnancy and before discharge from the healthcare facility. The second dose should be given 4 to 8 weeks after the first dose.
  • Hepatitis A vaccination should be given to anyone seeking protection from hepatitis A virus (HAV) infection, men who have sex with men, users of injection drugs, persons working with HAV-infected primates or with HAV in a research laboratory setting, persons with chronic liver disease and persons who receive clotting factor concentrates, and persons traveling to or working in countries with high or intermediate endemicity of hepatitis A.
  • Hepatitis B vaccination should be given to anyone seeking protection from hepatitis B virus (HBV) infection, persons with more than 1 sex partner during the previous 6 months, persons seeking evaluation or treatment of a sexually transmitted disease, current or recent injection-drug users, men who have sex with men, healthcare personnel and public safety workers exposed to blood or other potentially infectious body fluids, persons with end-stage renal disease, persons with HIV infection, persons with chronic liver disease, household contacts and sex partners of persons with chronic HBV infection, clients and staff members of institutions for persons with developmental disabilities, and international travelers to countries with a high or intermediate prevalence of chronic HBV infection.
Some of the ACIP members have disclosed various financial relationships with CDC, sanofi-pasteur, Novartis, Medimmune, ADMA, the National Institutes of Health, Bill & Melinda Gates Foundation, Exxon Mobil Research Club, Protein Sciences, Pfizer, Schering-Plough, Medical Education Speakers' Network, National Foundation for Infectious Diseases, Rady Children's Hospital San Diego, Phoenix Children's Hospital, Symposia Medicus, and/or CDC.
Ann Intern Med. 2011:154:168-173. Full text


http://www.medscape.org/viewarticle/736793?src=cmemp

regards, taniafdi ^_^

New Guidelines on Carotid and Vertebral Artery Disease

News Author: Susan Jeffrey
CME Author: Charles P. Vega, MD
CME Released: 02/11/2011; Valid for credit through 02/11/2012

February 11, 2011 — New guidelines on the management of patients with extracranial carotid and vertebral artery disease (ECVD) were released on January 31 by the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
The document was developed in collaboration with a gamut of other organizations, including the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery, as well as the American Academy of Neurology and Society of Cardiovascular Computed Tomography.
Of note are new recommendations for management of carotid disease, where carotid stenting is now seen as an alternative to carotid endarterectomy for symptomatic patients at average or low risk for complications, with stenosis greater than 70% on duplex ultrasonography.
Thomas G. Brott, MD, professor of neurology and director of research at the Mayo Clinic in Jacksonville, Florida, was cochair of the writing committee for the new guidelines and also principal investigator of the Carotid Revascularization Endarterectomy versus Stent Trial (CREST).
The results of CREST suggest that in addition to carotid surgery and medical therapy, "we now have a third option, carotid stenting, he said. "Both surgery and stenting have been shown to be safe, and so far, in CREST, both have been shown to be durable."
The new guidelines are concordant with recently released guidelines on primary and secondary stroke prevention, as well as a recommendation last week by the US Food and Drug Administration Circulatory System Devices Panel, Dr. Brott said. At a meeting January 26, the panel voted 7 to 3 in favor of an expanded indication for the RX Acculink Carotid Stenting System, stating the benefits of carotid stenting in patients at standard risk for adverse events from endarterectomy outweigh the risks. Currently, the system is approved only for those at high surgical risk.
The role of stenting vs surgery has been controversial, given results of previous randomized comparisons, such as the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial and the International Carotid Stenting Study (ICSS), that had suggested surgery to be the safer option.
"I would say in other situations where we have 3 choices for treatment of a particular condition, physician groups and patients don't always agree on the options for a particular patient, and that's likely to occur with carotid disease as well," Dr. Brott said in an interview.
The guidelines suggest it may be "reasonable" to choose surgery over stenting in older patients, particularly those with anatomy unfavorable for stenting, and likewise reasonable to choose stenting over surgery when neck anatomy is not suitable for surgery.
The document is published online January 31 in Circulation: Journal of the American Heart Association, Stroke: Journal of the American Heart Association, and Journal of the American College of Cardiology.
Routine Screening Not Recommended
The new recommendations deal with diagnostic testing and medical and surgical therapies, as well as risk factor modification, in patients with ECVD.
Some of their other recommendations include the following:
  • The guidelines advocate duplex ultrasonography, performed by a qualified technologist in a certified laboratory, as the initial diagnostic test for suspected carotid stenosis. However, the writing group recommends against routine screening of asymptomatic patients without clinical symptoms or risk factors for atherosclerosis.
  • In patients with extracranial carotid disease not undergoing revascularization, the guidelines recommend antiplatelet therapy with aspirin, 75 to 325 mg daily, for patients with obstructive or nonobstructive atherosclerosis in extracranial carotid and/or vertebral arteries for prevention of myocardial infarction and other cardiovascular events. The benefit of treatment to prevent stroke in asymptomatic patients hasn't been established, they note.
  • For those with extracranial carotid or vertebral atherosclerosis with a history of ischemic stroke or transient ischemic attack, antiplatelet therapy with aspirin alone (75 to 325 mg daily), clopidogrel alone (75 mg daily), or the combination of aspirin plus extended-release dipyridamole (25 and 200 mg twice daily, respectively) is recommended and preferred over the combination of aspirin with clopidogrel.
  • Carotid duplex ultrasound screening before coronary artery bypass grafting is reasonable in patients older than 65 years, those with left main coronary stenosis, and a history of stroke or transient ischemic attack or carotid bruit. Revascularization with surgery or stenting with embolic protection is reasonable for those who have experienced ipsilateral ischemic symptoms, but for asymptomatic patients, the safety and efficacy of carotid revascularization before or during CABG are "not well established."
'Vast Opportunities' for Research
Although the study authors note that their recommendations are "whenever possible, evidence based," review of the literature has shown that great gaps in knowledge remain.
"As evident from the number of recommendations in this document that are based on consensus in a void of definitive evidence, there are vast opportunities for research," they write.
Among these is the lack of evidence to support the benefit of carotid surgery in women, a clear need for more information on the "imperfect correlation" between the severity of carotid stenosis and ischemic events, and better methods to improve diagnostic accuracy of stenosis.
"CREST answered some questions about the relative value of [carotid artery stenting and carotid endarterectomy] but raised others," they write. "The reported event rates were generally low with either method of revascularization among symptomatic patients, but there was an important difference related to patient age that requires explanation.
"The most pressing question is how either technique of revascularization compares with intensive contemporary medical therapy, particularly among asymptomatic patients, and a direct comparative trial should include a sufficiently broad range of patients to permit meaningful analysis of subgroups based on age, sex, ethnicity, and risk status," the study authors write.
"Huge gaps" in knowledge about vertebral arterial disease will be more difficult to solve because of its relative infrequency compared with carotid stenosis, they add. "This requires well-designed registries that capture data about prevalence, pathophysiology, natural history, and prognosis."
Dr. Brott reports having received research funding from Abbott and the National Institutes of Health as principal investigator of CREST. Dr. Halperin reports serving as a consultant to Astellas Pharma, Bayer Health Care, Biotronik, Boehringer Ingelheim, Daiichi Sankyo, the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee, GlaxoSmithKline, Johnson & Johnson, Portola, and Sanofi-aventis. He has also received research funding from the National Heart, Lung, and Blood Institute. Disclosures for other members of the writing committee appear in the document.
J Am Coll Cardiol. Published online January 31, 2011. Full text
Stroke. Published online January 31, 2011. Full text
Circulation. Published online January 31, 2011. Full text



http://www.medscape.org/viewarticle/737243?src=cmemp

regards, taniafdi ^_^

Updated BPH Treatment Guideline Released

News Author: Emma Hitt, PhD
CME Author: Laurie Barclay, MD
CME/CE Released: 02/11/2011; Valid for credit through 02/11/2012

February 11, 2011 — The American Urological Association (AUA) has issued updated guidance on the treatment of benign prostatic hyperplasia (BPH).

The newly released guidelines update current recommendations, first published in 2003, for diagnosing and treating this disorder. The guidelines were released online February 3 and will be published in an upcoming print issue of the Journal of Urology.

The updated guidelines include a detailed diagnostic algorithm to guide physicians in diagnosing and treating lower urinary tract symptoms (LUTS) that result from BPH. They also provide in-depth information on BPH management strategies in general and on complicated cases in particular.

"Physicians treating men with suspected cases of LUTS should obtain a relevant medical history, assess symptoms using the AUA Symptom Index and conduct a full physical examination (including a digital rectal exam)," states a written release from the AUA. "Laboratory tests should include a prostate-specific antigen...test and a urinalysis to exclude infection or other causes for LUTS," and "frequency and volume charts may also be useful in providing a diagnosis."

The guidelines maintain that some patients may benefit using a combination of all 3 modalities. "Should improvement be insufficient and symptoms severe, then newer modalities of treatment such as botulinum toxin and sacral neuromodulation can be considered," the report states.

According to the AUA, the 2003 update provided key information on the use of surgical and medical approaches, whereas the 2010 updated version contains added recommendations for the use of anticholinergic drugs and the use of laser therapies. In addition, the index patient age has been lowered from 50 years to 45 years to improve guidance for the treatment of younger men with LUTS.

The guidelines also advise clinicians to remain vigilant about intraoperative floppy iris syndrome in patients with cataract who are taking alpha-blockers to treat BPH. Patients should be asked about any planned cataract surgery before starting an alpha-blocker regimen, and if surgery is planned, alpha-blockers should be avoided until after the procedure.

The panel also recommends against the routine measurement of serum creatinine levels in the initial evaluation of men with LUTS secondary to BPH.

The clinical guideline was developed after panelists had conducted a systematic review and had synthesized the clinical literature on current and emerging therapies for the treatment of BPH.

The panelists asked 3 questions regarding current therapy for BPH: "(1) What is the comparative efficacy...and effectiveness...of currently available and emerging treatments for BPH? What are the predictors of beneficial effects from treatments? (2) What are the adverse events associated with each of the included treatments, and how do the adverse events compare across treatments? (3) Are there subpopulations in which the efficacy, effectiveness, and adverse event rates vary from those in general populations?"
"The methodology followed the same process used in the development of the 2003 Guideline and, as such, did not include an evaluation of the strength of the body of evidence as will be instituted in future Guidelines produced by the AUA," the report states.

In a news release, chair of the guideline's panel Kevin T. McVary, MD, noted, "The increasing life expectancy and growth of our elderly population will increase the number of men who suffer from LUTS.

"This will place increased demands for treatment services, and necessitate the incorporation of evidence-based medicine" and "provides much-needed guidance to doctors who are already treating LUTS."
The report was compiled without commercial support.

Related Link
The Mayo Clinic provides an overview of prostate gland enlargement that discusses presentation, risk factors, complications, and management that is appropriate for patient education.


regards, taniafdi ^_^

Dutasteride May Slow the Growth of Early-Stage Prostate Cancer

For men who are undergoing active surveillance for early-stage prostate cancer, the drug dutasteride (Avodart) could help control the disease and prevent the need for more aggressive treatments. The finding, from a randomized, placebo-controlled trial, was presented during the 2011 Genitourinary Cancers Symposium, which was held February 17–19 in Orlando, FL. Dutasteride is already approved by the Food and Drug Administration (FDA) for the treatment of an enlarged prostate gland, or benign prostatic hyperplasia.

Active surveillance, previously called “watchful waiting,” refers to the practice of forgoing immediate treatment after a prostate cancer diagnosis in favor of regularly scheduled testing and clinical exams to closely monitor the disease. In the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial, 302 men undergoing active surveillance were randomly assigned to receive either dutasteride, which belongs to the class of drugs known as 5-alpha reductase inhibitors, or placebo for 3 years. Biopsy specimens were collected at 18 and 36 months, or as warranted based on evidence of disease progression.

In the dutasteride group, 38 percent of the men experienced some progression of their cancer, compared with 49 percent of the men in the placebo group. This difference translated into a reduction in relative risk for cancer progression of 38.9 percent in the dutasteride group. In addition, taking dutasteride increased the chances that no cancer would be found during a participant’s final biopsy. Thirty-six percent of the men in the dutasteride group and 23 percent of the men in the placebo group had no cancer detected in their final biopsy specimens.

It would be “very reasonable” to give a 5-alpha reductase inhibitor to patients with “ultra low-risk” prostate cancer who elect for active surveillance, said the trial’s lead investigator, Dr. Neil Fleshner of the University Health Network in Toronto, during a press briefing. However, Dr. Fleshner cautioned, this would be considered an “off-label” use of dutasteride. In December, the FDA’s Oncologic Drugs Advisory Committee rejected GlaxoSmithKline's application to approve dutasteride for use in preventing prostate cancer, and Dr. Fleshner said that the company was unlikely to seek an additional approval for the drug.

“The results of REDEEM suggest that dutasteride has an antitumor effect against low-volume, low-risk prostate cancer,” said Dr. Howard Parnes of NCI’s Division of Cancer Prevention, who was not involved in the study. “I think that this class of drugs [5-alpha reductase inhibitors] deserves to be studied further in men undergoing active surveillance.”

The Genitourinary Cancers Symposium was cosponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology.

regards, taniafdi ^_^

What Makes a Good Doctor Good?

Shara Yurkiewicz, Medical Student, 05:15PM Feb 15, 2011

For first years, shadowing is a basic part of our clinical experience. I recently had the pleasure of shadowing an oncologist one-on-one in an inpatient setting. He was fairly high up on the totem pole, and after two hours and five patients, I could see why.
From my observations:

  • The oncologist rarely used numbers. A treatment didn't have x percent chance of success, and a patient didn't have x weeks or x years. His words qualified, not quantified.
  • He was frank with patients. Seeing a white coating inside a patient's mouth, he suspected the horse (thrush, a side effect of treatment) but did not hesitate to mention the zebra (oral cancer). Again, instead of tossing around numbers, he simply said, "It's probably okay, but I still have to check."
  • He was franker with me regarding his expectations and frustrations. He mentioned that "I can get most patients to do what I want them to do, as long as I phrase it the right way or draw them the right pictures." But he expressed exasperation with intransient paients. Regarding a lady who, for inexplicable reasons, was willing to undergo an invasive bone marrow transplant but not a routine vaccination: "I'm working hard to save her life from cancer and she's going to **** it up and die because of something like that?" Another man's leukemia spread dramatically. With the patient, he was all business, making plans for treatment and not giving an explicit prognosis. When I asked more specifically about the prognosis, he predicted that he would probably die within the year.
  • He strongly believed that a physician, with vastly more knowledge and experience than a patient, should not remain neutral on treatment options. "Never say to a patient, 'Here are your two options. You decide what you want to do.' Tell them what you would recommend and why."
  • He never assigned blame. When I asked if a patient's cancer had spread because of his refusal to get treatment initially, he told me that it was dangerous to think that way and it's almost impossible to pin down murky causes like that.
  • He said "I don't know" once but had a clear plan. Even if that plan was just waiting and watching.
  • He was meticulous about details and trends. He continuously analyzed minor changes in blood cell count and cancer cell count (and informed the patients about these), and he did not jump to potentially unnecessary treatment without waiting a few weeks to gain a better handle on the bigger picture.
  • He was a brilliant and compassionate physician, and it was an honor to shadow him.
regards, taniafdi ^_^

The Karyotype: Are Chromosome Studies Necessary Anymore?

Bruce Buehler, MD, Pediatrics, General, 12:22PM Feb 16, 2011

For the past 30 years, prometaphase, microscopic studies of the chromosomes from each cell has been the genetic test for individuals with delays, multiple anomalies, or supected syndromes. This began with Down syndrome (trisomy 21) and Turner Syndrome (X0) karyotypes. Microarray (comparative genomic hybridization, or CGH) can identify thousands of genes unidentifiable by microscopic study of a chromosome. It can be done on a small blood sample in a short period of time. Working at the gene level improves diagnostic efficiency and identifies very small deletions or duplications not seen on a karyotype.
For the past 5 years, karyotype and microarray were ordered together for genetic studies. Yet microarray technology has rapidly evolved to looking at small changes within a gene, leading to sophisticated genetic disease identification, while karyotypes remain unchanged.
With the emergence of microarray technology, what is the role of a standard chromosome study as a first step in the diagnosis of multiple congenital anomalies or developmental delays? The American College of Medical Genetics recently published a statement that microarray studies are the genetic study of choice in unknown syndromes and developmental delays.* This is partly in response to the insurance companies that have been unwilling to pay for microarray, claiming it is experimental. It is now clear that microarray is a reliable genetic diagnostic test with greater potential than a karyotype.
A karyotype may remain useful for translocations and well known chromosome abnormalities like Down syndrome, Trisomy 13, or Trisomy 18, but even that will soon be replaced by the next generation of microarray technology.
For the clinician, it is best for your patient to order microarray as your first broad genetic test. Karyotype should be reserved for family studies and a few known large chromosome syndromes. The payors will be less willing to pay for both microarray and karyotype, so microarray is the most efficient test. This is a major shift for clinicians, but it is only one of the changes in laboratory testing emerging from new technology.

*The American College of Medical Genetics guideline was published in Genetics in Medicine in November 2010 and is available at http://www.acmg.net/StaticContent/PPG/Array_based_technology_and_recommendations_for.13.pdf.

regards, taniafdi ^_^

2/5/11

Journals

Treatment of Acute Otitis Media in Children under 2 Years of Age.



A Prospective Natural-History Study of Coronary Atherosclerosis.



Prevention of Dialysis Catheter Malfunction with Recombinant Tissue Plasminogen Activator.



Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation.



A Placebo-Controlled Trial of Antimicrobial Treatment for Acute Otitis Media.





Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta.




Fidaxomicin versus Vancomycin for Clostridium difficile Infection.





regards, taniafdi ^_^

Losing Body Fat Before Pregnancy Could Help Break Obesity Cycle

Losing body fat before pregnancy could help break the obesity cycle and improve the lifelong health of babies born to obese mothers, according to US researchers who are studying what happens across generations that could be contributing to the obesity crisis.


Obesity is a growing problem worldwide, and more and more women are obese when they fall pregnant.



Babies born to obese mothers are themselves more likely to become obese children and adults, another factor that drives the obesity and overweight epidemic.



However, a collaborative study between the Center for Pregnancy and Newborn Research at the University of Texas Health Science Center (UTHSC) at San Antonio and the National Institute of Nutrition in Mexico City, suggests that if obese mothers lose body fat before they fall pregnant, they can pass on health benefits to their children.



Dr Peter Nathanielsz, a professor in UTHSC's Center for Pregnancy and Newborn Research, and colleagues studied female rats raised on high-fat diets, comparing one obese group that continued eating the same diet through mating, pregnancy and lactation with another group that was switched to a healthier lower fat diet one month before mating.



They then studied the male offspring of both groups and found those born to mothers who remained obese and stayed on the high-fat diets through pregnancy to lactation, had higher levels of triglycerides, leptin, insulin and insulin resistance at the weaning stage, whereas in babies born to mothers who were put on low fat diets before pregnancy so they lost body fat, these levels were normal. 



They also found the babies born to obese mothers had increased fat mass and fat cell size, whereas these changes were significantly reversed, although not totally, in babies born to mothers in the group that switched to a low fat diet before pregnancy.



The researchers told the press that, although the extent of reversibility depended on the tissue affected, this was the first time research had shown it was possible to reverse metabolic effects in offspring born to obese mothers by changing the mothers' diets before pregnancy.



Nathanielsz said it was interesting that the offspring born to obese mothers had high levels of leptin, a hormone that tells the brain to reduce appetite.



Perhaps this means the offspring developed a brain that was resistant to the signal that tells them they are getting fat and they just go on eating and getting fat, like their mothers.



"That is what we mean when we say that the effects are transgenerational," said Nathanielsz. 



"Leptin levels were normal in the offspring of the intervention group, showing that we can break this cycle," he added.



Nathanielsz explained they were able to achieve at least 50 to 60 per cent return to normal levels, which he regards as a first step.



Perhaps the next stage is to try a no-fat diet or add micronutrients to the diet, but this has to be done carefully because there could be unwanted consequences in trying to restore levels to normal too quickly.



"We believe this sort of information is necessary to provide guidelines as to the type of dietary intervention for women during pregnancy. Much remains to be done," he cautioned.



The role of leptin is not straightforward. It is natural for it to peak after birth in newborn rodents, and it seems this peak is an important feature in the development of the brain's hypothalamic appetite control centers.



But from this and other experiments with rodents, Nathanielsz and colleagues showed that newborn offspring of obese mothers have larger and longer-lasting leptin peaks.



In another recent study published online on 24 January in the Journal of Physiology, Nathanielsz and colleagues from the University of Wyoming, describe a similar experiment with sheep, which suggests that the presence of higher levels of cortisol in lambs born to obese ewes could be disrupting the normal peaking of leptin in the lambs' first few days of life, thereby "predisposing them to increased appetite and weight gain in later life".



"Maternal obesity eliminates the neonatal lamb plasma leptin peak."
Nathan M. Long, Stephen P Ford, and Peter W Nathanielsz.
The Journal of Physiology, published online before print, 24 January 2011.
DOI: 10.1113/jphysiol.2010.201681



Additional source: University of Texas Health Science Center at San Antonio (2 Feb 2011 press release), Wikipedia.



Written by: Catharine Paddock, PhD 
Copyright: Medical News Today 



regards, taniafdi ^_^

Postprostatectomy Incontinence Can Be Improved, Even a Year Later

News Author: Nick Mulcahy
CME Author: Désirée Lie, MD, MSEd



January 20, 2011 — In men suffering from urinary incontinence a year or more after prostatectomy, a behavioral training program resulted in a significant reduction in urinary incontinence episodes, according to a new study.
The program consisted of pelvic floor muscle training, bladder control strategies, and fluid management.
The mean number of incontinence episodes decreased from 28 to 13 per week (55% reduction; 95% confidence interval [CI], 44% to 66%) after behavioral therapy, which was significantly greater than the reduction from 25 to 21 (24% reduction; 95% CI, 10% to 39%) observed among controls (= .001)
The study is authored by Patricia Goode, MD, from the University of Alabama-Birmingham, and colleagues, and is published in the January 12 issue of Journal of the American Medical Association.
However, before "roundly endorsing" this approach, it is important to examine other outcomes in the study, according to an expert who penned an accompanying editorial. Those outcomes are not as impressive, writes David Penson, MD, MPH, from the Department of Urologic Surgery at Vanderbilt University in Nashville, Tennessee.
He notes that, despite being statistically significant, the above-mentioned 55% reduction in incontinence episodes means that the men in the therapy group still had about 2 episodes a day.
In the end, Dr. Penson acknowledges that "behavioral therapy appears better than no therapy." But he declares that "if this is as good as this therapy gets, it is important to rethink how to best treat men with this problem."
Primary prevention might be best, he suggests.
In other words, clinicians should increase the use of active surveillance in men with localized prostate cancer, such as the men in the current study.
Because of the vagaries of prostate-specific antigen screening, the overdiagnosis rate of screen-detected cancer that would not present clinically during the patient's lifetime is estimated to be 23% to 42%, says Dr. Penson.
Because most of these men will be treated and many will have adverse effects, the overtreatment of prostate cancer is the underlying problem here, he suggests.
"A patient with this type of low-risk cancer, therefore, is exposed to the adverse effects of aggressive interventions, such as surgery or radiation, with little or no benefit," writes Dr. Penson, echoing many other experts who have published studies and editorials in the past few years.
But What About the Guys With Problems?
Urinary incontinence is a huge problem after prostatectomy, say the study authors.
As many as 65% of men are incontinent to some degree up to 5 years after surgery, they write, and loss of bladder control can be a physical, emotional, psychosocial, and economic burden for men who experience it.
Dr. Penson notes that stress urinary incontinence can be especially "bothersome" and, 5 years after surgery, has a rate of 14% to 28%.
Behavioral therapy has been previously shown to improve postoperative recovery of continence. "Several randomized trials have examined the effectiveness of perioperative pelvic floor muscle training and shown a significant reduction in duration and severity of incontinence in the early postoperative period," write Dr. Goode and her study coauthors.
The contribution of this study is that it tests, for the first time, the effectiveness of behavioral therapy for incontinence persisting more than a year after prostatectomy.
Most of the subjects in the study had undergone surgery at least 5 years previously (range, 1 to 17 years).
In the study, which was performed on men attending continence clinics at 2 Veteran Affairs hospitals and 1 university hospital, consisted of 208 men stratified by type and frequency of incontinence and randomized into 3 groups: 8 weeks of behavioral therapy (pelvic floor muscle training and bladder control strategies); behavioral therapy plus in-office dual-channel electromyographic biofeedback and daily home pelvic floor electrical stimulation; and delayed treatment, which served as the control group.
Notably, the researchers found that the addition of biofeedback and pelvic floor electrical stimulation provided no additional benefit.
The primary outcome of the study was the number of incontinence episodes at 8 weeks, measured with a 7-day bladder diary. As mentioned above, it was statistically significantly better in the treatment groups than in the control group.
Importantly, this improvement was durable. After 8 weeks of therapy, a 1-year follow-up visit was conducted. The investigators found that there was 50% reduction (95% CI, 39.8% to 61.1%; 13.5 episodes per week) in the behavioral-therapy group, which was comparable to the reduction seen immediately after the initial 8 weeks.
"Our findings indicate that no matter how long it's been since surgery, behavioral interventions can help men reduce the number of incontinent episodes they experience," said Dr. Goode in a press statement. "There is no guarantee that they'll be completely dry, but behavioral therapy will help reduce incontinence and improve quality of life."
Another outcome measure used in the study was the American Urological Association symptom index (AUA-7), which measures lower urinary tract symptoms.
However, Dr. Penson was not impressed with the results with this measure.
At 8 weeks, the behavioral-therapy group had a decrease in AUA-7 score of 2.5 points. This score is considered just a "slight improvement," according to an earlier study that defined clinically meaningful change for this instrument, Dr. Penson points out. He also notes that, at 6 and 12 months after the initiation of behavioral therapy, the decline in the AUA-7 score was less than 4 points, "the threshold for moderate improvement."
Where to Find Help
Dr. Goode and her colleagues have a different perspective about the study outcomes.
They note that 16% of men in the treatment groups achieved complete continence with therapy.
They also point out that, on average, men with incontinence reduced the problem by about half in the therapy groups. "A recent study determined that a 40% reduction in incontinence frequency was the threshold required to achieve a clinically important improvement on the validated Incontinence Quality of Life Questionnaire," they write.
Yet another measure showed that the therapy worked well, say the study authors. "The improvement in the Incontinence Impact Questionnaire score, which reflects the impact of incontinence on daily life, was 22.9 to 29.9," they write. This range exceeds the "minimally important difference" of 6.5 to 17.0.
The study authors credit bladder control strategies as being an important part of the therapy success.
"Many of the participants in our trial reported that they had tried pelvic floor muscle exercises after their surgery but had stopped when they failed to improve sufficiently," say the authors, who suggest that muscle control must be strategic.
They describe the bladder control strategies for stress and urge incontinence. "The strategy for preventing stress incontinence was to contract pelvic floor muscles just before and during activities that caused leakage, such as coughing or lifting," they write. Calm is also encouraged. "The urge-control strategy involved instructions to not rush to the toilet but instead to stay still and contract the pelvic floor muscles repeatedly until urgency abated and then proceed to the bathroom at a normal pace."
The authors believe that behavioral therapy should be offered to all men with urinary incontinence after prostate surgery.
"Behavioral therapy should be offered to men with persistent postprostatectomy incontinence because it can yield significant, durable improvement in incontinence and quality of life," they write.
However, there are a couple of obstacles for men who might benefit from the therapy, suggest the authors. "Behavioral therapy works, but unfortunately many men are not aware that it is an option or don't know where to find the therapy," said Kathryn Burgio, PhD, a study coauthor, in a press statement.
Some physical therapists offer behavioral therapy, say the authors, and 2 organizations — the Wound, Ostomy and Continence Nurses Society and the National Association for Continence — maintain a database of practitioners.
This study was supported by grant R01 DK60044 from the National Institute of Diabetes and Digestive and Kidney Diseases and by the Department of Veterans Affairs Birmingham–Atlanta Geriatric Research, Education, and Clinical Center. Dr. Goode reports receiving a research grant from Pfizer. Study coauthors also report industry ties, as noted in the paper.
JAMA. 2011;305:151-159, 197-198. AbstractAbstract

http://www.medscape.org/viewarticle/735971?src=cmemp

regards, taniafdi ^_^

New AHA/ASA Performance Metrics for Comprehensive Stroke Centers

News Author: Pauline Anderson
CME Author: Charles P. Vega, MD



anuary 21, 2011 — The American Heart Association and the American Stroke Association (AHA/ASA) have developed a series of 26 standardized metrics for use by comprehensive stroke centers (CSCs) across the United States to measure and monitor quality of care.
The proposed metrics, and the research backing them, were published online January 13 and will appear in the March issue of Stroke: Journal of the American Heart Association.
CSCs represent a more intensive level of stroke care than what is available at primary stroke centers (PSCs). PSCs have standard neurosurgical capabilities or can transfer patients to a facility that offers such services, but their focus is mainly on ischemic stroke. In contrast, CSCs will have full on-site capability to perform neurosurgical procedures and endovascular procedures and have intensive care services for patients with ischemic or hemorrhagic stroke.
"This is going a step further," said the chair of the paper's writing group, Dana Leifer, MD, associate professor of neurology at Weill Cornell Medical College, New York City. "This is designating certain hospitals with more specialized and advanced methods for treating stroke patients, so patients with more complications or more complicated stroke."
Designating and Certifying Hospitals
Establishing the new metrics is part of an effort to create mechanisms for designating and certifying hospitals in the field of stroke care.
"It's similar to the idea that there are different levels of trauma centers," said Dr. Leifer. "What we are doing in this paper is essentially proposing a standardized set of metrics and other data that CSCs should collect so that the care they provide can be assessed."
In 2005, the Brain Attack Coalition, a joint effort of the AHA and ASA, proposed an infrastructure of personnel, equipment, and protocols for CSCs and called for quality improvement mechanisms and registries to record how patients should be treated. The new recommendations, developed after an extensive review of the literature, are based on experience with previous quality improvement initiatives, such as the Get With The Guidelines (GWTG) program.
CSCs will treat both ischemic and hemorrhagic strokes. For the former, they will use some of the more advanced endovascular techniques, for example, catheters to deliver intra-arterial tissue plasminogen activator or mechanically extract a clot blocking an artery, said Dr. Leifer.
"But a lot of what CSCs also do is treat hemorrhagic strokes, in particular strokes related to subarachnoid hemorrhage (SAH) and to arteriovenous malformations (AVMs)."
Some proposed metrics involve the percentage of patients who receive certain procedures, such as, for example, the number of eligible patients receiving intravenous thrombolysis within the appropriate time window, or who develop certain complications, such as the number of intravenous thrombolysis-treated patients who have a symptomatic intracranial hemorrhage (ICH) within 36 hours of treatment. Others pertain to the median time to have a particular procedure, such as the time from hospitalization to repair of blood vessels for patients with a ruptured aneurysm.
One important metric relates to the use of nimodipine in patients with SAH to prevent vasospasm, a major secondary complication of SAH. Yet another relates to complication rates for aneurysm coiling and clipping.
The metrics are organized by disease category with metrics 1 through 11 pertaining to ischemic stroke and 12 to 20 to hemorrhagic stroke (12 – 18 related to aneurysms and 19 – 20 to ICH or AVMs). Other metrics relate to the patient transfer process.
"CSCs will be taking patients who initially present to another hospital," said Dr. Leifer. "One of the things that needs to be looked at is the efficiency of the transfer process so that the right patients get there and get there in a timely fashion."
Some metrics are designated as "core," which means they have stronger evidence supporting them or have greater clinical significance.
Track Performance
Ralph Sacco, MD, president of the AHA and chief of neurology at the University of Miami's Miller School of Medicine and Jackson Memorial Hospital in Florida, said the new recommendations can help provide the basis to monitor and track performance.
"We have consistently shown that when you track and benchmark performance, such as among our Get With the Guidelines–Stroke centers, you can raise the standard of care for many stroke patients in the US," he said in an email to Medscape Medical News.
Dr. Sacco noted that today almost 85% of the US population lives within 1 hour of a GWTG-Stroke hospital. 
The goal of the AHA is to reduce deaths from cardiovascular diseases and stroke by 20% before the year 2020, he added. "Every improvement in the performance of the way we treat strokes will help us accomplish this important goal."  
Dr. Leifer reports having received research funding from the National Institutes of Health as a site principal investigator in the MR and Recanalization of Stroke Clots Using Embolectomy and the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis trials. Disclosures for other members of the writing committee are outlined in the document. Dr. Sacco has disclosed no relevant financial relationships.
Stroke. Published online January 13, 2011. Abstract



regards, taniafdi ^_^

Study: Can a Veggie-Rich Diet Make You More Beautiful?

There are so many healthy reasons to eat vegetables that it feels redundant to keep enumerating them. But if a stronger immune system, cancer-fighting antioxidants and heart-healthy fiber aren't reason enough for some, perhaps we can appeal to their vanity: a study published in the journal Evolution and Human Behaviour found that eating foods high in carotenoids — a nutrient found in some fruits, leafy greens and root vegetables — gave them a healthy glow that rivaled a sun tan and made them more attractive in tests. (More on Time.com: Eat Veggies, Cheat Death)
"We found that, given the choice between skin color caused by suntan and skin color caused by carotenoids, people preferred the carotenoid skin color," Dr. Ian Stephen, the study's lead researcher, now of the School of Psychology, University of Nottingham, Malaysia Campus, said in a statement. "So if you want a healthier and more attractive skin color, you are better off eating a healthy diet with plenty of fruit and vegetables than lying in the sun."
People with diets high in fruits and vegetables had demonstrably yellower skin, the researchers found. But the scientists weren't sure if the veggie glow would be perceived differently than one achieved by sitting in the sun. So they asked study participants to look at 51 different Caucasian faces and adjust the skin tones to the hues, ranging from those typical of a day in the sun to the glow from a carotenoid-rich diet, that they thought looked healthiest. (More on Time.com: 5 New Rules for Good Health)

Read more: http://healthland.time.com/2011/01/12/study-can-a-veggie-rich-diet-make-you-more-beautiful/#ixzz1D8rk9zQb

regards, taniafdi ^_^

2/25/11


Akad Nikah

Reception (Minang)


Reception (Jambi)

Greatfull thanks for :

Prewedding & Reception photos : Beeasphotography, Bandung.  (http://www.beeasphoto.com/ & http://www.facebook.com/pages/Beeasphotography/73975522859)

Pelaminan, Baju Resepsi Minang, Make Up Akad/Resepsi, Entertainment : Ibu Ani Zainudin, Bandung. http://ani-zainuddin.blogspot.com/ & http://www.facebook.com/pages/ANI-ZAINUDDIN-Wedding-Organizer-Decoration/107039292650332

Katering : Teratai Catering, Cirebon. http://terataicateringcirebon.blogspot.com/ , http://www.facebook.com/pages/Teratai-Catering-Cirebon/96625668750?v=info & http://terataicateringcirebon.wordpress.com/

Undangan : Sam Arista, Bandung. http://id-id.facebook.com/pages/Sam-arista-wedding-invitation/187259987969735?v=info & http://www.samarista.com/

Souvenir : Purezzento, Bandung. http://purezentos.com/ & http://en-gb.facebook.com/people/Purezento-Cuziloveu/690204238

Akad Nikah Decoration : My mother, aunt Cici, aunt Nova, me, Uni Lia.

Room Decoration : My mother, aunt Cici, aunt Nova.

Wedding room bedcover, gorden, dll : Kembar 7 Gorden, Cirebon.

Kebaya Akad : Mbak Diana, Cirebon.

regards, taniafdi ^_^

Nieuw...

Exposure to Environmental Microorganisms and Childhood Asthma.
Association between Body-Mass Index and Risk of Death in More Than 1 Million Asians.A Recipe for Medical Schools to Produce Primary Care Physicians.


regards, taniafdi ^_^

Mouse Studies Point to Prognostic Test for Prostate Cancer

Some mice, like some men, develop prostate cancer that never spreads beyond the prostate, and researchers have used these mice to learn why only some tumors metastasize and become fatal. By studying genetically engineered mice, the researchers identified four genes that drive the progression of prostate tumors. The corresponding genes in humans also appear to influence the spread of prostate cancer and could become prognostic markers for identifying potentially lethal tumors in patients, the researchers reported online in Nature on February 2.

New tests are needed to distinguish lethal prostate tumors from those that would never cause harm in a man’s lifetime. But, given the enormous intratumoral heterogeneity of human prostate cancers, Dr. Ronald DePinho of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute and his colleagues decided to look for prognostic markers in genetically engineered mice, which are more amenable to genetic analysis. Using unbiased approaches, the investigators discovered that a mouse gene called Smad4 constrains the spread of tumor cells.

Additional experiments and lines of evidence, including functional studies and cross-species comparisons of genes, implicated four genes, including Smad4, in the progression of prostate cancer in mice. The researchers concluded that the process is governed largely by the inactivation of the genes Smad4 and Pten and activation of two other genes, cyclinD1 and Spp1.

They next assessed the prognostic value of the corresponding genes in human prostate cancer, using the protein products of the genes as markers. When added to standard clinical parameters such as the Gleason score, the researchers found these markers improved predictions of death from metastatic prostate cancer among men who participated in the Physicians’ Health Study and in a second study.

“We used the mouse models to filter out the intractable genomic complexity that presents itself in early-stage human cancers,” said Dr. DePinho. “And this allowed us to identify a collection of markers that are functionally relevant to the biology of invasion.” A company has licensed the four markers for further development, he added.

http://www.cancer.gov/ncicancerbulletin/020811/page3#d

regards, taniafdi ^_^

Adult Immunization Schedule for 2011 Released

News Author: Laurie Barclay, MD
CME Author: Charles P. Vega, MD
Posted: 01/31/2011
CME/CE Released: 02/03/2011; Valid for credit through 02/03/2012

February 3, 2011 — In October 2010, the Advisory Committee on Immunization Practices (ACIP) approved the Adult Immunization Schedule for 2011, which includes several changes.

The 2011 schedule, which reflects current recommendations for the licensed vaccines, is published in the February 1 issue of the Annals of Internal Medicine. The 2011 schedule was also approved by the American Academy of Family Physicians, American College of Obstetricians and Gynecologists, and the American College of Physicians.

"The notation for seasonal influenza vaccine in the figure and footnotes was changed to reflect the expanded recommendation for annual influenza vaccination for everyone 6 months of age or older, which was approved by ACIP in February 2010," write Abigail Shefer, MD, Immunization Services Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, and colleagues. "In October 2010, ACIP issued a permissive recommendation for use of the tetanus, diphtheria, pertussis (Tdap) vaccine in adults aged 65 years or older; approved the recommendation that Tdap can be administered regardless of how much time has elapsed since the last tetanus and diphtheria (Td)–containing vaccine; and approved a recommendation for a 2-dose series of meningococcal vaccine in adults with certain high-risk medical conditions. The vaccines listed in the Figure have been reordered to keep all universally recommended vaccines together (for example, influenza, Td/Tdap, varicella, human papillomavirus [HPV], and zoster)."

Other changes include clarifications to the footnotes for the measles, mumps, rubella; HPV; and Haemophilus influenza type B (Hib) vaccines and for revaccination with pneumococcal polysaccharide (PPSV). A vaccine series does not need to be restarted, regardless of the time elapsed between doses.

Specific Updated Changes
Specific changes in the schedule for 2011 include the following:
  • All persons at least 6 months old, including all adults, should be vaccinated against seasonal influenza. Adults at least 65 years old may receive the high-dose influenza vaccine (Fluzone; sanofi-pasteur, Swiftwater, Pennsylvania), licensed in 2010 for use in this age group, as an option.
  • Persons at least 65 years old in close contact with an infant younger than 12 months should receive Tdap vaccine, and all persons at least 65 years old may receive Tdap vaccine. Tdap should be administered regardless of time elapsed since receiving the last Td-containing vaccine.
  • Either quadrivalent human papillomavirus (HPV4) vaccine or bivalent (HPV2) vaccine is recommended for girls and women.
  • For revaccination with PPSV, 1-time revaccination after 5 years applies only to persons 19 through 64 years old with indicated chronic conditions, namely chronic renal failure or the nephrotic syndrome, functional or anatomic asplenia, or immunocompromising conditions.
  • For adults with anatomic or functional asplenia or persistent complement component deficiencies and adults with HIV infection who are vaccinated with meningococcal conjugate vaccine (MCV4), a 2-dose series of meningococcal vaccine is recommended, with the 2 doses given 2 months apart. For those with other indications, a single dose of meningococcal vaccine is still recommended. Information in the new schedule clarifies that MCV4 is a quadrivalent vaccine.
  • Information regarding the Hib vaccine clarifies which high-risk persons may receive 1 dose of Hib vaccine, namely persons who have sickle cell disease, leukemia, or HIV infection, or those who have had a splenectomy, if they have not previously received Hib vaccine.
Additional Schedule Highlights
Additional highlights of the Adult Immunization Schedule include the following:
  • Adults younger than 65 years whose previous Td status is unknown should receive 1 dose of Tdap. Tdap should be administered immediately to postpartum women, close contacts of infants younger than 12 months, and healthcare workers.
  • Girls 11 to 12 years old should receive HPV4 or HPV2. Catch-up vaccination in girls may be given until age 26 years. Boys and men 9 to 26 years old may be given HPV4 to lower their risk of acquiring genital warts.
  • All persons at least 60 years old should receive a single dose of vaccine against herpes zoster, regardless of whether personal history is positive for herpes zoster.
  • Recommendations for varicella vaccination are unchanged. Two vaccine doses at least 4 weeks apart should be given to all adults born during or after 1980 who have no evidence of immunity to varicella. Healthcare workers should not be considered to have immunity against varicella simply because of their age. Pregnant women should be evaluated for evidence of varicella immunity, and those lacking such evidence should receive the first dose of varicella vaccine on completion or termination of pregnancy and before discharge from the healthcare facility. The second dose should be given 4 to 8 weeks after the first dose.
  • Hepatitis A vaccination should be given to anyone seeking protection from hepatitis A virus (HAV) infection, men who have sex with men, users of injection drugs, persons working with HAV-infected primates or with HAV in a research laboratory setting, persons with chronic liver disease and persons who receive clotting factor concentrates, and persons traveling to or working in countries with high or intermediate endemicity of hepatitis A.
  • Hepatitis B vaccination should be given to anyone seeking protection from hepatitis B virus (HBV) infection, persons with more than 1 sex partner during the previous 6 months, persons seeking evaluation or treatment of a sexually transmitted disease, current or recent injection-drug users, men who have sex with men, healthcare personnel and public safety workers exposed to blood or other potentially infectious body fluids, persons with end-stage renal disease, persons with HIV infection, persons with chronic liver disease, household contacts and sex partners of persons with chronic HBV infection, clients and staff members of institutions for persons with developmental disabilities, and international travelers to countries with a high or intermediate prevalence of chronic HBV infection.
Some of the ACIP members have disclosed various financial relationships with CDC, sanofi-pasteur, Novartis, Medimmune, ADMA, the National Institutes of Health, Bill & Melinda Gates Foundation, Exxon Mobil Research Club, Protein Sciences, Pfizer, Schering-Plough, Medical Education Speakers' Network, National Foundation for Infectious Diseases, Rady Children's Hospital San Diego, Phoenix Children's Hospital, Symposia Medicus, and/or CDC.
Ann Intern Med. 2011:154:168-173. Full text


http://www.medscape.org/viewarticle/736793?src=cmemp

regards, taniafdi ^_^

New Guidelines on Carotid and Vertebral Artery Disease

News Author: Susan Jeffrey
CME Author: Charles P. Vega, MD
CME Released: 02/11/2011; Valid for credit through 02/11/2012

February 11, 2011 — New guidelines on the management of patients with extracranial carotid and vertebral artery disease (ECVD) were released on January 31 by the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
The document was developed in collaboration with a gamut of other organizations, including the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery, as well as the American Academy of Neurology and Society of Cardiovascular Computed Tomography.
Of note are new recommendations for management of carotid disease, where carotid stenting is now seen as an alternative to carotid endarterectomy for symptomatic patients at average or low risk for complications, with stenosis greater than 70% on duplex ultrasonography.
Thomas G. Brott, MD, professor of neurology and director of research at the Mayo Clinic in Jacksonville, Florida, was cochair of the writing committee for the new guidelines and also principal investigator of the Carotid Revascularization Endarterectomy versus Stent Trial (CREST).
The results of CREST suggest that in addition to carotid surgery and medical therapy, "we now have a third option, carotid stenting, he said. "Both surgery and stenting have been shown to be safe, and so far, in CREST, both have been shown to be durable."
The new guidelines are concordant with recently released guidelines on primary and secondary stroke prevention, as well as a recommendation last week by the US Food and Drug Administration Circulatory System Devices Panel, Dr. Brott said. At a meeting January 26, the panel voted 7 to 3 in favor of an expanded indication for the RX Acculink Carotid Stenting System, stating the benefits of carotid stenting in patients at standard risk for adverse events from endarterectomy outweigh the risks. Currently, the system is approved only for those at high surgical risk.
The role of stenting vs surgery has been controversial, given results of previous randomized comparisons, such as the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) trial and the International Carotid Stenting Study (ICSS), that had suggested surgery to be the safer option.
"I would say in other situations where we have 3 choices for treatment of a particular condition, physician groups and patients don't always agree on the options for a particular patient, and that's likely to occur with carotid disease as well," Dr. Brott said in an interview.
The guidelines suggest it may be "reasonable" to choose surgery over stenting in older patients, particularly those with anatomy unfavorable for stenting, and likewise reasonable to choose stenting over surgery when neck anatomy is not suitable for surgery.
The document is published online January 31 in Circulation: Journal of the American Heart Association, Stroke: Journal of the American Heart Association, and Journal of the American College of Cardiology.
Routine Screening Not Recommended
The new recommendations deal with diagnostic testing and medical and surgical therapies, as well as risk factor modification, in patients with ECVD.
Some of their other recommendations include the following:
  • The guidelines advocate duplex ultrasonography, performed by a qualified technologist in a certified laboratory, as the initial diagnostic test for suspected carotid stenosis. However, the writing group recommends against routine screening of asymptomatic patients without clinical symptoms or risk factors for atherosclerosis.
  • In patients with extracranial carotid disease not undergoing revascularization, the guidelines recommend antiplatelet therapy with aspirin, 75 to 325 mg daily, for patients with obstructive or nonobstructive atherosclerosis in extracranial carotid and/or vertebral arteries for prevention of myocardial infarction and other cardiovascular events. The benefit of treatment to prevent stroke in asymptomatic patients hasn't been established, they note.
  • For those with extracranial carotid or vertebral atherosclerosis with a history of ischemic stroke or transient ischemic attack, antiplatelet therapy with aspirin alone (75 to 325 mg daily), clopidogrel alone (75 mg daily), or the combination of aspirin plus extended-release dipyridamole (25 and 200 mg twice daily, respectively) is recommended and preferred over the combination of aspirin with clopidogrel.
  • Carotid duplex ultrasound screening before coronary artery bypass grafting is reasonable in patients older than 65 years, those with left main coronary stenosis, and a history of stroke or transient ischemic attack or carotid bruit. Revascularization with surgery or stenting with embolic protection is reasonable for those who have experienced ipsilateral ischemic symptoms, but for asymptomatic patients, the safety and efficacy of carotid revascularization before or during CABG are "not well established."
'Vast Opportunities' for Research
Although the study authors note that their recommendations are "whenever possible, evidence based," review of the literature has shown that great gaps in knowledge remain.
"As evident from the number of recommendations in this document that are based on consensus in a void of definitive evidence, there are vast opportunities for research," they write.
Among these is the lack of evidence to support the benefit of carotid surgery in women, a clear need for more information on the "imperfect correlation" between the severity of carotid stenosis and ischemic events, and better methods to improve diagnostic accuracy of stenosis.
"CREST answered some questions about the relative value of [carotid artery stenting and carotid endarterectomy] but raised others," they write. "The reported event rates were generally low with either method of revascularization among symptomatic patients, but there was an important difference related to patient age that requires explanation.
"The most pressing question is how either technique of revascularization compares with intensive contemporary medical therapy, particularly among asymptomatic patients, and a direct comparative trial should include a sufficiently broad range of patients to permit meaningful analysis of subgroups based on age, sex, ethnicity, and risk status," the study authors write.
"Huge gaps" in knowledge about vertebral arterial disease will be more difficult to solve because of its relative infrequency compared with carotid stenosis, they add. "This requires well-designed registries that capture data about prevalence, pathophysiology, natural history, and prognosis."
Dr. Brott reports having received research funding from Abbott and the National Institutes of Health as principal investigator of CREST. Dr. Halperin reports serving as a consultant to Astellas Pharma, Bayer Health Care, Biotronik, Boehringer Ingelheim, Daiichi Sankyo, the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee, GlaxoSmithKline, Johnson & Johnson, Portola, and Sanofi-aventis. He has also received research funding from the National Heart, Lung, and Blood Institute. Disclosures for other members of the writing committee appear in the document.
J Am Coll Cardiol. Published online January 31, 2011. Full text
Stroke. Published online January 31, 2011. Full text
Circulation. Published online January 31, 2011. Full text



http://www.medscape.org/viewarticle/737243?src=cmemp

regards, taniafdi ^_^

Updated BPH Treatment Guideline Released

News Author: Emma Hitt, PhD
CME Author: Laurie Barclay, MD
CME/CE Released: 02/11/2011; Valid for credit through 02/11/2012

February 11, 2011 — The American Urological Association (AUA) has issued updated guidance on the treatment of benign prostatic hyperplasia (BPH).

The newly released guidelines update current recommendations, first published in 2003, for diagnosing and treating this disorder. The guidelines were released online February 3 and will be published in an upcoming print issue of the Journal of Urology.

The updated guidelines include a detailed diagnostic algorithm to guide physicians in diagnosing and treating lower urinary tract symptoms (LUTS) that result from BPH. They also provide in-depth information on BPH management strategies in general and on complicated cases in particular.

"Physicians treating men with suspected cases of LUTS should obtain a relevant medical history, assess symptoms using the AUA Symptom Index and conduct a full physical examination (including a digital rectal exam)," states a written release from the AUA. "Laboratory tests should include a prostate-specific antigen...test and a urinalysis to exclude infection or other causes for LUTS," and "frequency and volume charts may also be useful in providing a diagnosis."

The guidelines maintain that some patients may benefit using a combination of all 3 modalities. "Should improvement be insufficient and symptoms severe, then newer modalities of treatment such as botulinum toxin and sacral neuromodulation can be considered," the report states.

According to the AUA, the 2003 update provided key information on the use of surgical and medical approaches, whereas the 2010 updated version contains added recommendations for the use of anticholinergic drugs and the use of laser therapies. In addition, the index patient age has been lowered from 50 years to 45 years to improve guidance for the treatment of younger men with LUTS.

The guidelines also advise clinicians to remain vigilant about intraoperative floppy iris syndrome in patients with cataract who are taking alpha-blockers to treat BPH. Patients should be asked about any planned cataract surgery before starting an alpha-blocker regimen, and if surgery is planned, alpha-blockers should be avoided until after the procedure.

The panel also recommends against the routine measurement of serum creatinine levels in the initial evaluation of men with LUTS secondary to BPH.

The clinical guideline was developed after panelists had conducted a systematic review and had synthesized the clinical literature on current and emerging therapies for the treatment of BPH.

The panelists asked 3 questions regarding current therapy for BPH: "(1) What is the comparative efficacy...and effectiveness...of currently available and emerging treatments for BPH? What are the predictors of beneficial effects from treatments? (2) What are the adverse events associated with each of the included treatments, and how do the adverse events compare across treatments? (3) Are there subpopulations in which the efficacy, effectiveness, and adverse event rates vary from those in general populations?"
"The methodology followed the same process used in the development of the 2003 Guideline and, as such, did not include an evaluation of the strength of the body of evidence as will be instituted in future Guidelines produced by the AUA," the report states.

In a news release, chair of the guideline's panel Kevin T. McVary, MD, noted, "The increasing life expectancy and growth of our elderly population will increase the number of men who suffer from LUTS.

"This will place increased demands for treatment services, and necessitate the incorporation of evidence-based medicine" and "provides much-needed guidance to doctors who are already treating LUTS."
The report was compiled without commercial support.

Related Link
The Mayo Clinic provides an overview of prostate gland enlargement that discusses presentation, risk factors, complications, and management that is appropriate for patient education.


regards, taniafdi ^_^

Dutasteride May Slow the Growth of Early-Stage Prostate Cancer

For men who are undergoing active surveillance for early-stage prostate cancer, the drug dutasteride (Avodart) could help control the disease and prevent the need for more aggressive treatments. The finding, from a randomized, placebo-controlled trial, was presented during the 2011 Genitourinary Cancers Symposium, which was held February 17–19 in Orlando, FL. Dutasteride is already approved by the Food and Drug Administration (FDA) for the treatment of an enlarged prostate gland, or benign prostatic hyperplasia.

Active surveillance, previously called “watchful waiting,” refers to the practice of forgoing immediate treatment after a prostate cancer diagnosis in favor of regularly scheduled testing and clinical exams to closely monitor the disease. In the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial, 302 men undergoing active surveillance were randomly assigned to receive either dutasteride, which belongs to the class of drugs known as 5-alpha reductase inhibitors, or placebo for 3 years. Biopsy specimens were collected at 18 and 36 months, or as warranted based on evidence of disease progression.

In the dutasteride group, 38 percent of the men experienced some progression of their cancer, compared with 49 percent of the men in the placebo group. This difference translated into a reduction in relative risk for cancer progression of 38.9 percent in the dutasteride group. In addition, taking dutasteride increased the chances that no cancer would be found during a participant’s final biopsy. Thirty-six percent of the men in the dutasteride group and 23 percent of the men in the placebo group had no cancer detected in their final biopsy specimens.

It would be “very reasonable” to give a 5-alpha reductase inhibitor to patients with “ultra low-risk” prostate cancer who elect for active surveillance, said the trial’s lead investigator, Dr. Neil Fleshner of the University Health Network in Toronto, during a press briefing. However, Dr. Fleshner cautioned, this would be considered an “off-label” use of dutasteride. In December, the FDA’s Oncologic Drugs Advisory Committee rejected GlaxoSmithKline's application to approve dutasteride for use in preventing prostate cancer, and Dr. Fleshner said that the company was unlikely to seek an additional approval for the drug.

“The results of REDEEM suggest that dutasteride has an antitumor effect against low-volume, low-risk prostate cancer,” said Dr. Howard Parnes of NCI’s Division of Cancer Prevention, who was not involved in the study. “I think that this class of drugs [5-alpha reductase inhibitors] deserves to be studied further in men undergoing active surveillance.”

The Genitourinary Cancers Symposium was cosponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, and the Society of Urologic Oncology.

regards, taniafdi ^_^

What Makes a Good Doctor Good?

Shara Yurkiewicz, Medical Student, 05:15PM Feb 15, 2011

For first years, shadowing is a basic part of our clinical experience. I recently had the pleasure of shadowing an oncologist one-on-one in an inpatient setting. He was fairly high up on the totem pole, and after two hours and five patients, I could see why.
From my observations:

  • The oncologist rarely used numbers. A treatment didn't have x percent chance of success, and a patient didn't have x weeks or x years. His words qualified, not quantified.
  • He was frank with patients. Seeing a white coating inside a patient's mouth, he suspected the horse (thrush, a side effect of treatment) but did not hesitate to mention the zebra (oral cancer). Again, instead of tossing around numbers, he simply said, "It's probably okay, but I still have to check."
  • He was franker with me regarding his expectations and frustrations. He mentioned that "I can get most patients to do what I want them to do, as long as I phrase it the right way or draw them the right pictures." But he expressed exasperation with intransient paients. Regarding a lady who, for inexplicable reasons, was willing to undergo an invasive bone marrow transplant but not a routine vaccination: "I'm working hard to save her life from cancer and she's going to **** it up and die because of something like that?" Another man's leukemia spread dramatically. With the patient, he was all business, making plans for treatment and not giving an explicit prognosis. When I asked more specifically about the prognosis, he predicted that he would probably die within the year.
  • He strongly believed that a physician, with vastly more knowledge and experience than a patient, should not remain neutral on treatment options. "Never say to a patient, 'Here are your two options. You decide what you want to do.' Tell them what you would recommend and why."
  • He never assigned blame. When I asked if a patient's cancer had spread because of his refusal to get treatment initially, he told me that it was dangerous to think that way and it's almost impossible to pin down murky causes like that.
  • He said "I don't know" once but had a clear plan. Even if that plan was just waiting and watching.
  • He was meticulous about details and trends. He continuously analyzed minor changes in blood cell count and cancer cell count (and informed the patients about these), and he did not jump to potentially unnecessary treatment without waiting a few weeks to gain a better handle on the bigger picture.
  • He was a brilliant and compassionate physician, and it was an honor to shadow him.
regards, taniafdi ^_^

The Karyotype: Are Chromosome Studies Necessary Anymore?

Bruce Buehler, MD, Pediatrics, General, 12:22PM Feb 16, 2011

For the past 30 years, prometaphase, microscopic studies of the chromosomes from each cell has been the genetic test for individuals with delays, multiple anomalies, or supected syndromes. This began with Down syndrome (trisomy 21) and Turner Syndrome (X0) karyotypes. Microarray (comparative genomic hybridization, or CGH) can identify thousands of genes unidentifiable by microscopic study of a chromosome. It can be done on a small blood sample in a short period of time. Working at the gene level improves diagnostic efficiency and identifies very small deletions or duplications not seen on a karyotype.
For the past 5 years, karyotype and microarray were ordered together for genetic studies. Yet microarray technology has rapidly evolved to looking at small changes within a gene, leading to sophisticated genetic disease identification, while karyotypes remain unchanged.
With the emergence of microarray technology, what is the role of a standard chromosome study as a first step in the diagnosis of multiple congenital anomalies or developmental delays? The American College of Medical Genetics recently published a statement that microarray studies are the genetic study of choice in unknown syndromes and developmental delays.* This is partly in response to the insurance companies that have been unwilling to pay for microarray, claiming it is experimental. It is now clear that microarray is a reliable genetic diagnostic test with greater potential than a karyotype.
A karyotype may remain useful for translocations and well known chromosome abnormalities like Down syndrome, Trisomy 13, or Trisomy 18, but even that will soon be replaced by the next generation of microarray technology.
For the clinician, it is best for your patient to order microarray as your first broad genetic test. Karyotype should be reserved for family studies and a few known large chromosome syndromes. The payors will be less willing to pay for both microarray and karyotype, so microarray is the most efficient test. This is a major shift for clinicians, but it is only one of the changes in laboratory testing emerging from new technology.

*The American College of Medical Genetics guideline was published in Genetics in Medicine in November 2010 and is available at http://www.acmg.net/StaticContent/PPG/Array_based_technology_and_recommendations_for.13.pdf.

regards, taniafdi ^_^

2/5/11

Journals

Treatment of Acute Otitis Media in Children under 2 Years of Age.



A Prospective Natural-History Study of Coronary Atherosclerosis.



Prevention of Dialysis Catheter Malfunction with Recombinant Tissue Plasminogen Activator.



Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation.



A Placebo-Controlled Trial of Antimicrobial Treatment for Acute Otitis Media.





Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta.




Fidaxomicin versus Vancomycin for Clostridium difficile Infection.





regards, taniafdi ^_^

Losing Body Fat Before Pregnancy Could Help Break Obesity Cycle

Losing body fat before pregnancy could help break the obesity cycle and improve the lifelong health of babies born to obese mothers, according to US researchers who are studying what happens across generations that could be contributing to the obesity crisis.


Obesity is a growing problem worldwide, and more and more women are obese when they fall pregnant.



Babies born to obese mothers are themselves more likely to become obese children and adults, another factor that drives the obesity and overweight epidemic.



However, a collaborative study between the Center for Pregnancy and Newborn Research at the University of Texas Health Science Center (UTHSC) at San Antonio and the National Institute of Nutrition in Mexico City, suggests that if obese mothers lose body fat before they fall pregnant, they can pass on health benefits to their children.



Dr Peter Nathanielsz, a professor in UTHSC's Center for Pregnancy and Newborn Research, and colleagues studied female rats raised on high-fat diets, comparing one obese group that continued eating the same diet through mating, pregnancy and lactation with another group that was switched to a healthier lower fat diet one month before mating.



They then studied the male offspring of both groups and found those born to mothers who remained obese and stayed on the high-fat diets through pregnancy to lactation, had higher levels of triglycerides, leptin, insulin and insulin resistance at the weaning stage, whereas in babies born to mothers who were put on low fat diets before pregnancy so they lost body fat, these levels were normal. 



They also found the babies born to obese mothers had increased fat mass and fat cell size, whereas these changes were significantly reversed, although not totally, in babies born to mothers in the group that switched to a low fat diet before pregnancy.



The researchers told the press that, although the extent of reversibility depended on the tissue affected, this was the first time research had shown it was possible to reverse metabolic effects in offspring born to obese mothers by changing the mothers' diets before pregnancy.



Nathanielsz said it was interesting that the offspring born to obese mothers had high levels of leptin, a hormone that tells the brain to reduce appetite.



Perhaps this means the offspring developed a brain that was resistant to the signal that tells them they are getting fat and they just go on eating and getting fat, like their mothers.



"That is what we mean when we say that the effects are transgenerational," said Nathanielsz. 



"Leptin levels were normal in the offspring of the intervention group, showing that we can break this cycle," he added.



Nathanielsz explained they were able to achieve at least 50 to 60 per cent return to normal levels, which he regards as a first step.



Perhaps the next stage is to try a no-fat diet or add micronutrients to the diet, but this has to be done carefully because there could be unwanted consequences in trying to restore levels to normal too quickly.



"We believe this sort of information is necessary to provide guidelines as to the type of dietary intervention for women during pregnancy. Much remains to be done," he cautioned.



The role of leptin is not straightforward. It is natural for it to peak after birth in newborn rodents, and it seems this peak is an important feature in the development of the brain's hypothalamic appetite control centers.



But from this and other experiments with rodents, Nathanielsz and colleagues showed that newborn offspring of obese mothers have larger and longer-lasting leptin peaks.



In another recent study published online on 24 January in the Journal of Physiology, Nathanielsz and colleagues from the University of Wyoming, describe a similar experiment with sheep, which suggests that the presence of higher levels of cortisol in lambs born to obese ewes could be disrupting the normal peaking of leptin in the lambs' first few days of life, thereby "predisposing them to increased appetite and weight gain in later life".



"Maternal obesity eliminates the neonatal lamb plasma leptin peak."
Nathan M. Long, Stephen P Ford, and Peter W Nathanielsz.
The Journal of Physiology, published online before print, 24 January 2011.
DOI: 10.1113/jphysiol.2010.201681



Additional source: University of Texas Health Science Center at San Antonio (2 Feb 2011 press release), Wikipedia.



Written by: Catharine Paddock, PhD 
Copyright: Medical News Today 



regards, taniafdi ^_^

Postprostatectomy Incontinence Can Be Improved, Even a Year Later

News Author: Nick Mulcahy
CME Author: Désirée Lie, MD, MSEd



January 20, 2011 — In men suffering from urinary incontinence a year or more after prostatectomy, a behavioral training program resulted in a significant reduction in urinary incontinence episodes, according to a new study.
The program consisted of pelvic floor muscle training, bladder control strategies, and fluid management.
The mean number of incontinence episodes decreased from 28 to 13 per week (55% reduction; 95% confidence interval [CI], 44% to 66%) after behavioral therapy, which was significantly greater than the reduction from 25 to 21 (24% reduction; 95% CI, 10% to 39%) observed among controls (= .001)
The study is authored by Patricia Goode, MD, from the University of Alabama-Birmingham, and colleagues, and is published in the January 12 issue of Journal of the American Medical Association.
However, before "roundly endorsing" this approach, it is important to examine other outcomes in the study, according to an expert who penned an accompanying editorial. Those outcomes are not as impressive, writes David Penson, MD, MPH, from the Department of Urologic Surgery at Vanderbilt University in Nashville, Tennessee.
He notes that, despite being statistically significant, the above-mentioned 55% reduction in incontinence episodes means that the men in the therapy group still had about 2 episodes a day.
In the end, Dr. Penson acknowledges that "behavioral therapy appears better than no therapy." But he declares that "if this is as good as this therapy gets, it is important to rethink how to best treat men with this problem."
Primary prevention might be best, he suggests.
In other words, clinicians should increase the use of active surveillance in men with localized prostate cancer, such as the men in the current study.
Because of the vagaries of prostate-specific antigen screening, the overdiagnosis rate of screen-detected cancer that would not present clinically during the patient's lifetime is estimated to be 23% to 42%, says Dr. Penson.
Because most of these men will be treated and many will have adverse effects, the overtreatment of prostate cancer is the underlying problem here, he suggests.
"A patient with this type of low-risk cancer, therefore, is exposed to the adverse effects of aggressive interventions, such as surgery or radiation, with little or no benefit," writes Dr. Penson, echoing many other experts who have published studies and editorials in the past few years.
But What About the Guys With Problems?
Urinary incontinence is a huge problem after prostatectomy, say the study authors.
As many as 65% of men are incontinent to some degree up to 5 years after surgery, they write, and loss of bladder control can be a physical, emotional, psychosocial, and economic burden for men who experience it.
Dr. Penson notes that stress urinary incontinence can be especially "bothersome" and, 5 years after surgery, has a rate of 14% to 28%.
Behavioral therapy has been previously shown to improve postoperative recovery of continence. "Several randomized trials have examined the effectiveness of perioperative pelvic floor muscle training and shown a significant reduction in duration and severity of incontinence in the early postoperative period," write Dr. Goode and her study coauthors.
The contribution of this study is that it tests, for the first time, the effectiveness of behavioral therapy for incontinence persisting more than a year after prostatectomy.
Most of the subjects in the study had undergone surgery at least 5 years previously (range, 1 to 17 years).
In the study, which was performed on men attending continence clinics at 2 Veteran Affairs hospitals and 1 university hospital, consisted of 208 men stratified by type and frequency of incontinence and randomized into 3 groups: 8 weeks of behavioral therapy (pelvic floor muscle training and bladder control strategies); behavioral therapy plus in-office dual-channel electromyographic biofeedback and daily home pelvic floor electrical stimulation; and delayed treatment, which served as the control group.
Notably, the researchers found that the addition of biofeedback and pelvic floor electrical stimulation provided no additional benefit.
The primary outcome of the study was the number of incontinence episodes at 8 weeks, measured with a 7-day bladder diary. As mentioned above, it was statistically significantly better in the treatment groups than in the control group.
Importantly, this improvement was durable. After 8 weeks of therapy, a 1-year follow-up visit was conducted. The investigators found that there was 50% reduction (95% CI, 39.8% to 61.1%; 13.5 episodes per week) in the behavioral-therapy group, which was comparable to the reduction seen immediately after the initial 8 weeks.
"Our findings indicate that no matter how long it's been since surgery, behavioral interventions can help men reduce the number of incontinent episodes they experience," said Dr. Goode in a press statement. "There is no guarantee that they'll be completely dry, but behavioral therapy will help reduce incontinence and improve quality of life."
Another outcome measure used in the study was the American Urological Association symptom index (AUA-7), which measures lower urinary tract symptoms.
However, Dr. Penson was not impressed with the results with this measure.
At 8 weeks, the behavioral-therapy group had a decrease in AUA-7 score of 2.5 points. This score is considered just a "slight improvement," according to an earlier study that defined clinically meaningful change for this instrument, Dr. Penson points out. He also notes that, at 6 and 12 months after the initiation of behavioral therapy, the decline in the AUA-7 score was less than 4 points, "the threshold for moderate improvement."
Where to Find Help
Dr. Goode and her colleagues have a different perspective about the study outcomes.
They note that 16% of men in the treatment groups achieved complete continence with therapy.
They also point out that, on average, men with incontinence reduced the problem by about half in the therapy groups. "A recent study determined that a 40% reduction in incontinence frequency was the threshold required to achieve a clinically important improvement on the validated Incontinence Quality of Life Questionnaire," they write.
Yet another measure showed that the therapy worked well, say the study authors. "The improvement in the Incontinence Impact Questionnaire score, which reflects the impact of incontinence on daily life, was 22.9 to 29.9," they write. This range exceeds the "minimally important difference" of 6.5 to 17.0.
The study authors credit bladder control strategies as being an important part of the therapy success.
"Many of the participants in our trial reported that they had tried pelvic floor muscle exercises after their surgery but had stopped when they failed to improve sufficiently," say the authors, who suggest that muscle control must be strategic.
They describe the bladder control strategies for stress and urge incontinence. "The strategy for preventing stress incontinence was to contract pelvic floor muscles just before and during activities that caused leakage, such as coughing or lifting," they write. Calm is also encouraged. "The urge-control strategy involved instructions to not rush to the toilet but instead to stay still and contract the pelvic floor muscles repeatedly until urgency abated and then proceed to the bathroom at a normal pace."
The authors believe that behavioral therapy should be offered to all men with urinary incontinence after prostate surgery.
"Behavioral therapy should be offered to men with persistent postprostatectomy incontinence because it can yield significant, durable improvement in incontinence and quality of life," they write.
However, there are a couple of obstacles for men who might benefit from the therapy, suggest the authors. "Behavioral therapy works, but unfortunately many men are not aware that it is an option or don't know where to find the therapy," said Kathryn Burgio, PhD, a study coauthor, in a press statement.
Some physical therapists offer behavioral therapy, say the authors, and 2 organizations — the Wound, Ostomy and Continence Nurses Society and the National Association for Continence — maintain a database of practitioners.
This study was supported by grant R01 DK60044 from the National Institute of Diabetes and Digestive and Kidney Diseases and by the Department of Veterans Affairs Birmingham–Atlanta Geriatric Research, Education, and Clinical Center. Dr. Goode reports receiving a research grant from Pfizer. Study coauthors also report industry ties, as noted in the paper.
JAMA. 2011;305:151-159, 197-198. AbstractAbstract

http://www.medscape.org/viewarticle/735971?src=cmemp

regards, taniafdi ^_^

New AHA/ASA Performance Metrics for Comprehensive Stroke Centers

News Author: Pauline Anderson
CME Author: Charles P. Vega, MD



anuary 21, 2011 — The American Heart Association and the American Stroke Association (AHA/ASA) have developed a series of 26 standardized metrics for use by comprehensive stroke centers (CSCs) across the United States to measure and monitor quality of care.
The proposed metrics, and the research backing them, were published online January 13 and will appear in the March issue of Stroke: Journal of the American Heart Association.
CSCs represent a more intensive level of stroke care than what is available at primary stroke centers (PSCs). PSCs have standard neurosurgical capabilities or can transfer patients to a facility that offers such services, but their focus is mainly on ischemic stroke. In contrast, CSCs will have full on-site capability to perform neurosurgical procedures and endovascular procedures and have intensive care services for patients with ischemic or hemorrhagic stroke.
"This is going a step further," said the chair of the paper's writing group, Dana Leifer, MD, associate professor of neurology at Weill Cornell Medical College, New York City. "This is designating certain hospitals with more specialized and advanced methods for treating stroke patients, so patients with more complications or more complicated stroke."
Designating and Certifying Hospitals
Establishing the new metrics is part of an effort to create mechanisms for designating and certifying hospitals in the field of stroke care.
"It's similar to the idea that there are different levels of trauma centers," said Dr. Leifer. "What we are doing in this paper is essentially proposing a standardized set of metrics and other data that CSCs should collect so that the care they provide can be assessed."
In 2005, the Brain Attack Coalition, a joint effort of the AHA and ASA, proposed an infrastructure of personnel, equipment, and protocols for CSCs and called for quality improvement mechanisms and registries to record how patients should be treated. The new recommendations, developed after an extensive review of the literature, are based on experience with previous quality improvement initiatives, such as the Get With The Guidelines (GWTG) program.
CSCs will treat both ischemic and hemorrhagic strokes. For the former, they will use some of the more advanced endovascular techniques, for example, catheters to deliver intra-arterial tissue plasminogen activator or mechanically extract a clot blocking an artery, said Dr. Leifer.
"But a lot of what CSCs also do is treat hemorrhagic strokes, in particular strokes related to subarachnoid hemorrhage (SAH) and to arteriovenous malformations (AVMs)."
Some proposed metrics involve the percentage of patients who receive certain procedures, such as, for example, the number of eligible patients receiving intravenous thrombolysis within the appropriate time window, or who develop certain complications, such as the number of intravenous thrombolysis-treated patients who have a symptomatic intracranial hemorrhage (ICH) within 36 hours of treatment. Others pertain to the median time to have a particular procedure, such as the time from hospitalization to repair of blood vessels for patients with a ruptured aneurysm.
One important metric relates to the use of nimodipine in patients with SAH to prevent vasospasm, a major secondary complication of SAH. Yet another relates to complication rates for aneurysm coiling and clipping.
The metrics are organized by disease category with metrics 1 through 11 pertaining to ischemic stroke and 12 to 20 to hemorrhagic stroke (12 – 18 related to aneurysms and 19 – 20 to ICH or AVMs). Other metrics relate to the patient transfer process.
"CSCs will be taking patients who initially present to another hospital," said Dr. Leifer. "One of the things that needs to be looked at is the efficiency of the transfer process so that the right patients get there and get there in a timely fashion."
Some metrics are designated as "core," which means they have stronger evidence supporting them or have greater clinical significance.
Track Performance
Ralph Sacco, MD, president of the AHA and chief of neurology at the University of Miami's Miller School of Medicine and Jackson Memorial Hospital in Florida, said the new recommendations can help provide the basis to monitor and track performance.
"We have consistently shown that when you track and benchmark performance, such as among our Get With the Guidelines–Stroke centers, you can raise the standard of care for many stroke patients in the US," he said in an email to Medscape Medical News.
Dr. Sacco noted that today almost 85% of the US population lives within 1 hour of a GWTG-Stroke hospital. 
The goal of the AHA is to reduce deaths from cardiovascular diseases and stroke by 20% before the year 2020, he added. "Every improvement in the performance of the way we treat strokes will help us accomplish this important goal."  
Dr. Leifer reports having received research funding from the National Institutes of Health as a site principal investigator in the MR and Recanalization of Stroke Clots Using Embolectomy and the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis trials. Disclosures for other members of the writing committee are outlined in the document. Dr. Sacco has disclosed no relevant financial relationships.
Stroke. Published online January 13, 2011. Abstract



regards, taniafdi ^_^

Study: Can a Veggie-Rich Diet Make You More Beautiful?

There are so many healthy reasons to eat vegetables that it feels redundant to keep enumerating them. But if a stronger immune system, cancer-fighting antioxidants and heart-healthy fiber aren't reason enough for some, perhaps we can appeal to their vanity: a study published in the journal Evolution and Human Behaviour found that eating foods high in carotenoids — a nutrient found in some fruits, leafy greens and root vegetables — gave them a healthy glow that rivaled a sun tan and made them more attractive in tests. (More on Time.com: Eat Veggies, Cheat Death)
"We found that, given the choice between skin color caused by suntan and skin color caused by carotenoids, people preferred the carotenoid skin color," Dr. Ian Stephen, the study's lead researcher, now of the School of Psychology, University of Nottingham, Malaysia Campus, said in a statement. "So if you want a healthier and more attractive skin color, you are better off eating a healthy diet with plenty of fruit and vegetables than lying in the sun."
People with diets high in fruits and vegetables had demonstrably yellower skin, the researchers found. But the scientists weren't sure if the veggie glow would be perceived differently than one achieved by sitting in the sun. So they asked study participants to look at 51 different Caucasian faces and adjust the skin tones to the hues, ranging from those typical of a day in the sun to the glow from a carotenoid-rich diet, that they thought looked healthiest. (More on Time.com: 5 New Rules for Good Health)

Read more: http://healthland.time.com/2011/01/12/study-can-a-veggie-rich-diet-make-you-more-beautiful/#ixzz1D8rk9zQb

regards, taniafdi ^_^